Entera Bio (ENTX) 10-Q 9 Aug 24 2024 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2024	Aug. 05, 2024
Cover [Abstract]
Entity Registrant Name	ENTERA BIO LTD.
Document Type	10-Q
Document Period End Date	Jun. 30, 2024
Entity Central Index Key	0001638097
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Amendment Flag	false
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		36,324,579
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity Shell Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	false
Entity Incorporation, State or Country Code	L3
Entity Address, Address Line One	Kiryat Hadassah
Entity Address, Address Line Two	Minrav Building – Fifth Floor
Entity Address, City or Town	Jerusalem
Entity Address, Postal Zip Code	9112002
Entity Address, Country	IL
City Area Code	972
Local Phone Number	2-532-7151
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-38556
Entity Tax Identification Number	00-0000000
Trading Symbol	ENTX
Security Exchange Name	NASDAQ
Title of 12(b) Security	Ordinary Shares

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 9,056	$ 11,019
Accounts receivable	57	0
Other current assets	482	238
TOTAL CURRENT ASSETS	9,595	11,257
NON-CURRENT ASSETS:
Property and equipment, net	76	100
Operating lease right-of-use assets	344	388
Deferred income taxes	14	14
Funds in respect of employee rights upon retirement	6	6
TOTAL NON-CURRENT ASSETS	440	508
TOTAL ASSETS	10,035	11,765
CURRENT LIABILITIES:
Accounts payable	69	83
Accrued expenses and other payables	1,070	874
Current maturities of operating lease	155	134
TOTAL CURRENT LIABILITIES	1,294	1,091
NON-CURRENT LIABILITIES:
Operating lease liabilities	179	256
Liability for employee rights upon retirement	30	32
TOTAL NON-CURRENT LIABILITIES	209	288
TOTAL LIABILITIES	1,503	1,379
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY:
Ordinary Shares, NIS 0.0000769 par value: Authorized - as of June 30, 2024 and December 31, 2023, 140,010,000 shares; issued and outstanding as of June 30, 2024 and December 31, 2023, 36,314,579 and 35,476,341 shares, respectively	1	1
Additional paid-in capital	117,038	114,730
Accumulated other comprehensive income	41	41
Accumulated deficit	(108,548)	(104,386)
TOTAL SHAREHOLDERS' EQUITY	8,532	10,386
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 10,035	$ 11,765

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - ₪ / shares	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Ordinary share, par value	₪ 0.0000769	₪ 0.0000769
Ordinary shares, authorized	140,010,000	140,010,000
Ordinary shares, issued	36,314,579	35,476,341
Ordinary shares, outstanding	36,314,579	35,476,341

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
REVENUES	$ 57	$ 0	$ 57	$ 0
COST OF REVENUES	48	0	48	0
GROSS PROFIT	9	0	9	0
OPERATING EXPENSES:
Research and development	1,086	1,209	1,821	2,140
General and administrative	1,088	1,135	2,415	2,429
Other income	0	(14)	0	(27)
TOTAL OPERATING EXPENSES	2,174	2,330	4,236	4,542
OPERATING LOSS	2,165	2,330	4,227	4,542
FINANCIAL INCOME, NET	(20)	(5)	(65)	(27)
NET LOSS	$ 2,145	$ 2,325	$ 4,162	$ 4,515
LOSS PER SHARE BASIC	$ 0.06	$ 0.08	$ 0.11	$ 0.16
LOSS PER SHARE DILUTED	$ 0.06	$ 0.08	$ 0.11	$ 0.16
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC LOSS PER SHARE	37,090,160	28,812,375	36,913,725	28,811,162
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF DILUTED LOSS PER SHARE	37,090,160	28,812,375	36,913,725	28,811,162

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Ordinary shares [Member]		Additional paid-in capital [Member]	Accumulated other Comprehensive income [Member]	Accumulated deficit [Member]	Total
Balance at Dec. 31, 2022		[1]	$ 107,210	$ 41	$ (95,497)	$ 11,754
Balance (in shares) at Dec. 31, 2022	28,809,922
CHANGES DURING THE YEAR ENDED
Net loss	$ 0		0	0	(4,515)	(4,515)
Issuance of Ordinary Shares under the ATM program, net of issuance costs		[1]	5	0	0	5
Issuance of Ordinary Shares under the ATM program, net of issuance costs (in shares)	4,030
Share-based compensation	$ 0		988	0	0	988
Balance at Jun. 30, 2023		[1]	108,203	41	(100,012)	8,232
Balance (in shares) at Jun. 30, 2023	28,813,952
Balance at Mar. 31, 2023		[1]	107,726	41	(97,687)	10,080
Balance (in shares) at Mar. 31, 2023	28,809,922
CHANGES DURING THE YEAR ENDED
Net loss	$ 0		0	0	(2,325)	(2,325)
Issuance of Ordinary Shares under the ATM program, net of issuance costs		[1]	5	0	0	5
Issuance of Ordinary Shares under the ATM program, net of issuance costs (in shares)	4,030
Share-based compensation	$ 0		472	0	0	472
Balance at Jun. 30, 2023		[1]	108,203	41	(100,012)	8,232
Balance (in shares) at Jun. 30, 2023	28,813,952
Balance at Dec. 31, 2023	$ 1		114,730	41	(104,386)	10,386
Balance (in shares) at Dec. 31, 2023	35,476,341
CHANGES DURING THE YEAR ENDED
Net loss	$ 0		0	0	(4,162)	(4,162)
Exercise of warrants to Ordinary Shares		[1]	90	0	0	90
Exercise of warrants to Ordinary Shares (in shares)	89,820
Exercise of options to Ordinary Shares		[1]	555	0	0	555
Exercise of options to Ordinary Shares (in shares)	447,292
Issuance of Ordinary Shares under the ATM program, net of issuance costs		[1]	601	0	0	601
Issuance of Ordinary Shares under the ATM program, net of issuance costs (in shares)	236,126
Vested restricted share units		[1]	0	0	0	0
Vested restricted share units (in shares)	65,000
Share-based compensation	$ 0		1,062	0	0	1,062
Balance at Jun. 30, 2024	$ 1		117,038	41	(108,548)	8,532
Balance (in shares) at Jun. 30, 2024	36,314,579
Balance at Mar. 31, 2024	$ 1		115,224	41	(106,403)	8,863
Balance (in shares) at Mar. 31, 2024	35,526,281
CHANGES DURING THE YEAR ENDED
Net loss	$ 0		0	0	(2,145)	(2,145)
Exercise of warrants to Ordinary Shares		[1]	60	0	0	60
Exercise of warrants to Ordinary Shares (in shares)	59,880
Exercise of options to Ordinary Shares		[1]	555	0	0	555
Exercise of options to Ordinary Shares (in shares)	447,292
Issuance of Ordinary Shares under the ATM program, net of issuance costs		[1]	601	0	0	601
Issuance of Ordinary Shares under the ATM program, net of issuance costs (in shares)	236,126
Vested restricted share units		[1]	0	0	0	0
Vested restricted share units (in shares)	45,000
Share-based compensation	$ 0		598	0	0	598
Balance at Jun. 30, 2024	$ 1		$ 117,038	$ 41	$ (108,548)	$ 8,532
Balance (in shares) at Jun. 30, 2024	36,314,579
[1]Represents an amount less than one thousand U.S. dollars.

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,145)	$ (2,325)	$ (4,162)	$ (4,515)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation			24	29
Share-based compensation			1,062	988
Finance income, net			(14)	(6)
Changes in operating asset and liabilities:
Decrease (increase) in accounts receivable			(57)	217
Increase in other current assets			(232)	(356)
Increase (decrease) in accounts payable			(14)	223
Increase in accrued expenses and other payables			196	252
Net cash used in operating activities			(3,197)	(3,168)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment			0	(12)
Net cash used in investing activities			0	(12)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of shares under the ATM program, net of issuance costs			601	5
Exercise of options into shares			555	0
Exercise of warrants into shares			90	0
Net cash provided by financing activities			1,246	5
DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS			(1,951)	(3,175)
CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS AT BEGINNING OF THE PERIOD			11,085	12,376
CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS AT END OF THE PERIOD	9,134	9,201	9,134	9,201
Reconciliation in amounts on consolidated balance sheets:
Cash and cash equivalents	9,056	9,135	9,056	9,135
Restricted deposits included in other current assets	78	66	78	66
Total cash and cash equivalents and restricted deposits	$ 9,134	$ 9,201	9,134	9,201
SUPPLEMENTAL DISCLOSURE OF CASH FLOW TRANSACTIONS:
Interest received			66	0
SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:
Operating lease right of use assets obtained in exchange for new operating lease liabilities			$ 33	$ 449

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1 - DESCRIPTION OF BUSINESS a. Entera Bio Ltd. (collectively with its subsidiary, the “Company”) was incorporated on September 30, 2009 and commenced operations on June 1, 2010. On January 8, 2018, the Company incorporated its wholly owned subsidiary, Entera Bio Inc., in Delaware, United States. The Company is focused on developing first-in-class oral tablet formats of peptides or protein replacement therapies. The Company focuses on underserved, chronic medical conditions for which oral administration of a protein therapy has the potential to significantly shift a treatment paradigm. The Company’s most advanced product candidate, EB613, oral PTH (1-34), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for post-menopausal women with low bone mineral density (“BMD”) and high-risk osteoporosis with no prior fracture. The Company is preparing to initiate a Phase 3 registrational study for EB613 following the FDA’s expected qualification of a quantitative BMD endpoint. The EB612 program is being developed as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. Additionally, the Company intends to license its N-Tab™ technology to biopharmaceutical companies for use with their proprietary compounds. b. The Company's ordinary shares, NIS 0.0000769 par value per share (“ordinary shares”), are listed on the Nasdaq Capital Market under the symbol “ENTX”. c. Because the Company is engaged in research and development activities, it has not derived significant income from its activities and has incurred an accumulated deficit since our inception in 2010 in the amount of $108.5 thousand as of June 30, 2024 and negative cash flows from operating activities. The Company's management is of the opinion that its available funds as of June 30, 2024 will allow the Company to operate under its current plans into the third quarter of 2025. This assumes the use of the Company’s capital to fund its ongoing operations, including regulatory expenses and optimization related to the preparation of the EB613 phase 3 study, research and development, the completion of an additional Phase 1 PK study related to the Company’s new generation platform and the GLP-2/OXM collaborative research the Company is conducting with OPKO Biologics, Inc., a subsidiary of OPKO Health Inc. The Company’s current capital resources do not include the capital required to fund the Company's proposed Phase 3 study for EB613 in osteoporosis. These factors raise substantial doubt as to the Company's ability to continue as a going concern. Management continually evaluates various financing alternatives in the public and private equity markets, debt financing and strategic collaborations, as the Company will need to finance future research and development activities, general and administrative expenses and working capital through capital raising. However, there is no certainty that the Company will be able to obtain such funding. These consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern. d. In October 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on the Israeli population and industrial centers located along Israel’s border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in thousands of deaths and injuries, and Hamas additionally kidnapped many Israeli civilians and soldiers. Following the attack, Israel’s security cabinet declared war against Hamas and commenced a military campaign against Hamas. In addition, in April 2024, Israel experienced a direct attack from Iran, involving hundreds of drones and missiles launched towards various parts of the country, mostly targeting military bases. The Israeli defense systems, aided by international allies, successfully intercepted the majority of these attacks, minimizing physical damage and casualties. Additionally, since October 2023, the Houthis, a military organization based in Yemen, have launched a series of attacks on global shipping routes in the Red Sea, as well as direct attacks on various parts of Israel. Despite the effectiveness of Israel's missile defense systems, such incidents contribute to regional instability and could potentially escalate into broader conflicts with Iran and its proxies in the Middle East, affecting Israel's political and trade relations, especially with neighboring countries and global allies. The situation remains fluid, and the potential for further escalation exists. While the Company has a few employees who are in active military service, the ongoing war with Hamas and the conflict with Iran and its proxies have not, to date, materially impacted the Company’s business or operations. Furthermore, the Company does not expect any delays to any of its programs as a result of such conflicts. While R&D and management are located in Israel, other core activities including clinical, regulatory and our supply chain are not. However, the Company cannot currently predict the intensity or duration of Israel’s war against Hamas and/or the conflict with Iran and its proxies, nor can it predict how such conflicts will ultimately affect the Company’s business and operations or Israel’s economy in general.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES a. Basis of presentation of the financial statements These unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") for interim financial statements. Accordingly, they do not include all of the information and notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company’s consolidated financial position as of June 30, 2024, and the consolidated results of operations, statements of changes in shareholders' equity for the three and six-month periods ended June 30, 2024 and 2023 and cash flows for the six-month periods ended June 30, 2024 and 2023. The consolidated results for the three and six-month periods ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company as of and for the year ended December 31, 2023, as filed with the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 8, 2024. b. Loss per share Basic loss per share is computed on the basis of net loss for the period divided by the weighted average number of outstanding ordinary shares and pre-funded warrants during the period. Diluted loss per share is based upon the weighted average number of ordinary shares and ordinary share equivalents outstanding when dilutive. Ordinary share equivalents include outstanding stock options, warrants and restricted share units (“RSUs”), which are included under the treasury stock method when dilutive. The calculation of diluted loss per share does not include options and warrants exercisable into 16,785,585 shares and 7,360,374 shares for the six months ended June 30, 2024 and 2023, respectively, and 17,068,031 shares and 7,604,195 shares for the three months ended June 30, 2024 and 2023, respectively, because the effect would have been anti-dilutive. c. Newly issued and recently adopted accounting pronouncements: Recently issued accounting pronouncements not yet adopted In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis. Early adoption is permitted, with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. In November 2023, the FASB issued ASU 2023-07 “Segment Reporting: Improvements to Reportable Segment Disclosures”. This guidance expands public entities’ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.

EQUITY AND SHARE-BASED COMPENSA

EQUITY AND SHARE-BASED COMPENSATION	6 Months Ended
	Jun. 30, 2024
Share-based Payment Arrangement [Abstract]
EQUITY AND SHARE-BASED COMPENSATION	NOTE 3 - EQUITY AND SHARE-BASED COMPENSATION 1. Changes in Share Capital: a. During the six months ended June 30, 2024, 89,820 warrants issued in connection with the Company’s December 2023 private placement (the “December 2023 PIPE”) were exercised for 89,820 ordinary shares for a total consideration of $90. b. On September 2, During the three months ended June 30, 2024 the Company issued 236,126 ordinary shares pursuant to the Leerink ATM Program for net proceeds of $601 at a weighted average price of $2.54 per ordinary share. c. During the three months ended June 30, 2024, a former employee of the Company exercised 447,292 options for 447,292 ordinary shares for total consideration of $555. 2. Share-based Compensation: a. On January 1, 2024, an aggregate of 758,331 options to purchase ordinary shares were granted to seven non-executive members of the Board of Directors with an exercise price of $0.60 per share. The options vest in equal quarterly installments over a one-year period that began on January 1, 2024. This grant was approved by the shareholders of the Company on October 4, 2021. The fair value of the options at the date of grant was $295. b. On February 1, 2024, the Company entered into a consulting agreement with an investor relations consulting firm. Under the terms of the agreement, the Company agreed to pay a monthly fee of $5 and issued to the consultant 25,000 RSUs. The RSUs vest in five equal monthly installments over a five-month period that began on February 1, 2024. As of June 30, 2024, all 25,000 RSUs had vested. The fair value of the RSUs was $22. c. On February 15, 2024, the Company entered into a consulting agreement with an additional investor relations firm. Under the terms of the agreement, the Company agreed to issue the consultant 50,000 RSUs. The RSUs vest in five equal monthly installments over a five-month period that started on February 15, 2024. As of June 30, 2024, 40,000 RSUs had vested. The fair value of the RSUs was $53. d. On April 19, 2024, the board of directors approved the following options grants: (i) options to purchase an aggregate of 768,000 ordinary shares were granted to employees, executive officers and a service provider with an exercise price of $1.99 per share. The fair value of the options at the grant date was $1,098; and (ii) options to purchase an aggregate of 500,000 ordinary shares were granted to the Company’s Chief Executive Officer with an exercise price of $1.99 per share which was the share price on grant date. This grant was subject to shareholder approval, which was obtained at a meeting of the Company’s shareholders held on July 31, 2024. These options vest over three years from the date of grant; 33.33% vest on the first anniversary of the date of grant and the remaining 66.67% of the options will vest in eight equal quarterly installments following the first anniversary of the grant date. (iii) options to purchase an aggregate of 90,000 ordinary shares were granted to two advisory board members with an exercise price of $1.99 per share which was the share price on the grant date. These options vested immediately at the grant date. The fair value of the options at the grant date was $124. In addition, the board of directors approved the grant of 209,548 RSUs to executive officers (or entities controlled by such executive officers) in lieu of an annual cash bonus, of which 124,121 RSUs that were granted to the CEO and was subject to shareholder approval, which was obtained at a meeting of the Company’s shareholders held on July 31, 2024. The RSUs vest in four equal quarterly installments over a one-year period that started on April 19, 2024. The fair value of the RSUs was $417 using the fair value of the RSU’s on the board approval date. The fair value of each option granted was estimated at the date of grant using the Black-Scholes option-pricing model, using the following assumptions: Six months 2024 Six months 2023 Exercise price $0.60-$1.99 $0.73-$0.79 Dividend yield - - Expected volatility 74.28%-84.5% 74%-76% Risk-free interest rate 3.93%-4.66% 3.58%-3.98% Expected life - in years 5.3-5.87 5.3-6.11

SUPPLEMENTARY FINANCIAL STATEME

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION	6 Months Ended
	Jun. 30, 2024
Supplementary Financial Statement Information [Abstract]
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION	NOTE 4 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION: Balance sheets: June 30, December 31, Other current assets: 2024 2023 Prepaid expenses 268 34 Advance income tax 69 69 Restricted deposits 78 66 Other 67 69 482 238 June 30, December 31, Accrued expenses and other payables: 2024 2023 Employees and employees related 166 159 Provision for vacation 260 215 Accrued expenses 644 500 1,070 874

EVENTS DURING THE PERIOD

EVENTS DURING THE PERIOD	6 Months Ended
	Jun. 30, 2024
Events During Period [Abstract]
EVENTS DURING THE PERIOD	NOTE 5 - EVENTS DURING THE PERIOD In April 2024, the Company entered into a material transfer and research project agreement (the “research services agreement”) with a third party. According to the agreement, the third party will pay the Company a monthly payment for the research services, as well as reimbursement for external expenses based on an agreed budget. The Company recognize revenues according to ASC 606, "Revenues from Contracts with Customers”. Revenues attributed to the research services agreement are recognized over the duration of the research services agreement. The For the three months ended June 30, 2024, the Company recognized total revenues of $57 from this agreement.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (2,145)	$ (2,325)	$ (4,162)	$ (4,515)

Insider Trading Arrangements

Insider Trading Arrangements	6 Months Ended
	Jun. 30, 2024
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	During the quarter ended June 30, 2024, none of our officers or directors adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule 10b5-1 trading arrangement”, as defined in Item 408 of Regulation S-K.
Title	officers or directors
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Terminated	false

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of presentation of the financial statements	a. Basis of presentation of the financial statements These unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") for interim financial statements. Accordingly, they do not include all of the information and notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company’s consolidated financial position as of June 30, 2024, and the consolidated results of operations, statements of changes in shareholders' equity for the three and six-month periods ended June 30, 2024 and 2023 and cash flows for the six-month periods ended June 30, 2024 and 2023. The consolidated results for the three and six-month periods ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company as of and for the year ended December 31, 2023, as filed with the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 8, 2024.
Loss per share	b. Loss per share Basic loss per share is computed on the basis of net loss for the period divided by the weighted average number of outstanding ordinary shares and pre-funded warrants during the period. Diluted loss per share is based upon the weighted average number of ordinary shares and ordinary share equivalents outstanding when dilutive. Ordinary share equivalents include outstanding stock options, warrants and restricted share units (“RSUs”), which are included under the treasury stock method when dilutive. The calculation of diluted loss per share does not include options and warrants exercisable into 16,785,585 shares and 7,360,374 shares for the six months ended June 30, 2024 and 2023, respectively, and 17,068,031 shares and 7,604,195 shares for the three months ended June 30, 2024 and 2023, respectively, because the effect would have been anti-dilutive.
Newly issued and recently adopted accounting pronouncements	c. Newly issued and recently adopted accounting pronouncements: Recently issued accounting pronouncements not yet adopted In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis. Early adoption is permitted, with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. In November 2023, the FASB issued ASU 2023-07 “Segment Reporting: Improvements to Reportable Segment Disclosures”. This guidance expands public entities’ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.

EQUITY AND SHARE-BASED COMPEN_2

EQUITY AND SHARE-BASED COMPENSATION (Tables)	6 Months Ended
	Jun. 30, 2024
Share-based Payment Arrangement [Abstract]
Schedule of fair value assumptions of option granted using Black-Scholes option-pricing model	Six months 2024 Six months 2023 Exercise price $0.60-$1.99 $0.73-$0.79 Dividend yield - - Expected volatility 74.28%-84.5% 74%-76% Risk-free interest rate 3.93%-4.66% 3.58%-3.98% Expected life - in years 5.3-5.87 5.3-6.11

SUPPLEMENTARY FINANCIAL STATE_2

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2024
Supplementary Financial Statement Information [Abstract]
Schedule of prepaid expenses and other current assets	June 30, December 31, Other current assets: 2024 2023 Prepaid expenses 268 34 Advance income tax 69 69 Restricted deposits 78 66 Other 67 69 482 238
Schedule of accounts payable and accrued liabilities	June 30, December 31, Accrued expenses and other payables: 2024 2023 Employees and employees related 166 159 Provision for vacation 260 215 Accrued expenses 644 500 1,070 874

DESCRIPTION OF BUSINESS (Detail

DESCRIPTION OF BUSINESS (Detail Textuals) $ in Thousands	Jun. 30, 2024 ₪ / shares	Jun. 30, 2024 USD ($)	Dec. 31, 2023 ₪ / shares	Dec. 31, 2023 USD ($)
General [Line Items]
Ordinary share, par value | ₪ / shares	₪ 0.0000769		₪ 0.0000769
Accumulated deficit | $		$ 108,548		$ 104,386

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Significant Accounting Policies [Line Items]
Number of antidilutive securities excluded from computation of earnings per share	17,068,031	7,604,195	16,785,585	7,360,374

EQUITY AND SHARE-BASED COMPEN_3

EQUITY AND SHARE-BASED COMPENSATION (Detail Textuals) - USD ($) $ / shares in Units, $ in Thousands				1 Months Ended		3 Months Ended	6 Months Ended
	Feb. 01, 2024	Jan. 01, 2024	Sep. 02, 2022	Apr. 19, 2024	Feb. 15, 2024	Jun. 30, 2024	Jun. 30, 2024	Jun. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from Warrant Exercises							$ 90	$ 0
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Description of terms of share-based payment arrangement				The RSUs vest in four equal quarterly installments over a one-year period that started on April 19, 2024.
Fair value of the RSU at the grant date				$ 417
Sales Agreement [Member] | Leerink Partners LLC [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sale of ordinary shares under ATM program			5,000,000			236,126
Net proceeds under ATM program						$ 601
Weighted average price per ordinary share						$ 2.54
Private Placement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants issued						89,820	89,820
Number of ordinary shares will be purchased by exercising warrants						89,820	89,820
Proceeds from Warrant Exercises							$ 90
Vest on first anniversary of date of grant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vestion period				3 years
Vesting percentage				33.33%
Vest in twelve equal quarterly installments following the first anniversary of the applicable grant date [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage				66.67%
Seven non-executive board members [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of options at the date of grant		$ 295
Number of options to purchase ordinary shares		758,331
Exercise price of options granted		$ 0.6
Description of terms of share-based payment arrangement		The options vest in equal quarterly installments over a one-year period that began on January 1, 2024. This grant was approved by the shareholders of the Company on October 4, 2021.
Executive officers [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted Share Units granted				209,548
Consulting Agreement [Member] | Investor relations consulting firm [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Monthly fee	$ 5
Restricted Share Units granted	25,000
Restricted Share Units vested							25,000
Fair value of the RSU at the grant date							$ 22
Consulting Agreement [Member] | Additional investor relations consulting firm [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Description of terms of share-based payment arrangement					The RSUs vest in five equal monthly installments over a five-month period that started on February 15, 2024.
Restricted Share Units granted					50,000
Restricted Share Units vested							40,000
Fair value of the RSU at the grant date							$ 53
Employees, executive officers and service providers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options to purchase ordinary shares				768,000
Exercise price of options granted				$ 1.99
Fair value of the RSU at the grant date				$ 1,098
Two advisory board members [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options to purchase ordinary shares				90,000
Exercise price of options granted				$ 1.99
Fair value of the RSU at the grant date				$ 124
Former Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants issued						447,292	447,292
Number of ordinary shares will be purchased by exercising warrants						447,292	447,292
Proceeds from Warrant Exercises						$ 555
Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options to purchase ordinary shares				500,000
Exercise price of options granted				$ 1.99
Chief Executive Officer [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted Share Units granted				124,121

EQUITY AND SHARE-BASED COMPEN_4

EQUITY AND SHARE-BASED COMPENSATION (Details) - $ / shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0%	0%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 0.6	$ 0.73
Expected volatility	74.28%	74%
Risk-free interest rate	3.93%	3.58%
Expected life - in years	5 years 3 months 18 days	5 years 3 months 18 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 1.99	$ 0.79
Expected volatility	84.50%	76%
Risk-free interest rate	4.66%	3.98%
Expected life - in years	5 years 10 months 13 days	6 years 1 month 9 days

SUPPLEMENTARY FINANCIAL STATE_3

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Other current assets:
Prepaid expenses	$ 268	$ 34
Advance income tax	69	69
Restricted deposits	78	66
Other	67	69
Other current assets	482	238
Accrued expenses and other payables:
Employees and employees related	166	159
Provision for vacation	260	215
Accrued expenses	644	500
Accrued expenses and other payables	$ 1,070	$ 874

EVENTS DURING THE PERIOD (Detai

EVENTS DURING THE PERIOD (Detail Textuals) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Events During Period [Abstract]
Revenue	$ 57	$ 0	$ 57	$ 0